Sentiment Survey
Ranking History
Headlines
- 1 Stock Mutual Fund is Positive In America... Was Positive
Nov 14, 2008 10:06 AM
- Schering-Plough Forecast Trimmed - Analyst Blog
Oct 23, 2008 04:18 PM
- Estimates Sliding Away - Earnings Trends
Oct 22, 2008 11:28 PM
- Morgan Stanley is Going from Bearish to Bullish Equities
Sep 19, 2008 09:07 AM
- Analyst Comments: Hess Corp, Mylan, AvalonBay, Abbott Labs, Trimble, NCR Corp, Vertex Pharma, American Tower, Sony, Washington Federal, Boston Properties, Johnson & Johnson, Matsushita, Deckers, Mechel Steel, Kroger
Sep 18, 2008 01:37 PM
- Analyst Comments: Juniper, Anaren, Microsemi, Akamai, Akzo Nobel, Nabors, Banco Santander
Sep 09, 2008 12:05 PM
- China’s Hepatitis B Market to Double by 2012
Aug 29, 2008 02:30 PM
- Pfocus on Pfizer
Aug 27, 2008 02:07 PM
- Is It Time To Invest In Pharmaceuticals?
Aug 18, 2008 08:42 AM
- The Week in Review: Earnings, Earnings, Earnings
Aug 17, 2008 02:18 PM
- Fears Drive Down New Jersey Stocks
Nov 16, 2008 01:12 PM
- Health Care Poised to Weather Recession
Nov 02, 2008 10:54 AM
- Health care, defense poised to weather recession
Nov 01, 2008 01:54 PM
- Merck 3Q net drops 28 percent; to cut 7,200 jobs
Oct 22, 2008 02:56 PM
- Why Clean Tech Is Taking Biotech's Shine
Oct 07, 2008 10:53 AM
- Movers: Wachovia, Wells Fargo, Citigroup, AIG
Oct 06, 2008 10:56 AM
- Economic Woes Take a Heavy Toll on Jobs
Oct 04, 2008 10:54 AM
- Unemployment Expected to Get Worse
Oct 04, 2008 10:54 AM
- Economy sheds most jobs since 2003, more cuts seen
Oct 03, 2008 10:55 PM
- Economy sheds most jobs since 2003, more cuts seen
Oct 03, 2008 03:00 PM
- Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Nov 24, 2008 01:02 PM
- Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Nov 24, 2008 11:22 AM
- Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
Nov 24, 2008 10:36 AM
- Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
Nov 24, 2008 10:36 AM
- Seven Summits Research Releases Alerts on RIMM, JPM, SGP, BG, and MR
Nov 11, 2008 09:31 AM
- Schering-Plough to Webcast R&D Update Meeting
Nov 07, 2008 11:58 AM
- Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Nov 01, 2008 11:00 AM
- Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case
Oct 30, 2008 05:30 PM
- Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
Oct 28, 2008 08:30 AM
- Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Oct 26, 2008 11:15 AM
- Form 4 SCHERING PLOUGH CORP For: Nov 21 Filed by: Colligan Thomas J (10K)
Nov 24, 2008 03:45 PM
- Form 4 SCHERING PLOUGH CORP For: Oct 28 Filed by: STAHL JACK L (10K)
Oct 30, 2008 04:32 PM
- Form 4 SCHERING PLOUGH CORP For: May 30 Filed by: Thompson Craig B. (10K)
May 30, 2008 05:54 PM
- Form 4 SCHERING PLOUGH CORP For: May 30 Filed by: MUNDY CARL E JR (10K)
May 30, 2008 05:48 PM
- Form 4 SCHERING PLOUGH CORP For: May 30 Filed by: WEINBACH ARTHUR F (10K)
May 30, 2008 05:35 PM
- Form 4 SCHERING PLOUGH CORP For: May 30 Filed by: MCGRATH EUGENE R (10K)
May 30, 2008 05:35 PM
- Form 4 SCHERING PLOUGH CORP For: May 30 Filed by: VAN OORDT ROBERT FW (10K)
May 30, 2008 05:35 PM
- Form 4 SCHERING PLOUGH CORP For: May 30 Filed by: LEDER PHILIP (10K)
May 30, 2008 05:34 PM
- Form 4 SCHERING PLOUGH CORP For: May 30 Filed by: TURNER KATHRYN C (10K)
May 30, 2008 05:34 PM
- Form 4 SCHERING PLOUGH CORP For: May 30 Filed by: STAHL JACK L (10K)
May 30, 2008 05:33 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
SGP
|
Compare to S&P
|
| YTD |
-36.90 %
|
3.38 %
|
| 4 Weeks |
16.01 %
|
25.40 %
|
| 12 Weeks |
-12.72 %
|
20.98 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -13.33 %
|
|
EPS Growth in Last Year: 39.29 %
|
|
Sales Growth in Last Quarter: -7.01 %
|
|
Sales Growth in Last Quarter: 62.73 %
|
|
|
